Biocon Biologics, Viatris receive approval for cancer drug, Health News, ET HealthWorld

Biocon Biologics, Viatris receive approval for cancer drugBiocon Biologics has received approval for its cancer drug Abevmy co-developed with Viatris. Abevmy 100 & 400 mg, a biosimilar of Bevacizumab has received marketing authorization approval from the European Commission (EC) following the positive recommendation by the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency, said the company in a filing to the stock exchange.

Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

“The European Commission’s approval of our biosimilar Bevacizumab will enable us to offer this biologic therapy to cancer patients in the EU along with our partner Viatris. The addition of biosimilar Bevacizumab will strengthen our portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim. This approval underlines our commitment to expand affordable access to life-saving biosimilars and make an enduring impact on global health,” said a company spokesperson.